RxDoctor Payments Data

Shahena Master, DO

Internal Medicine · Windsor, CTNPI 1174522973

Payments from drug & device makers

$521in general payments, 2019–2025

Across 26 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$123
  • GSK$64
  • Lilly USA, LLC$60
  • Novartis$46
  • Abbott$46
  • Genentech USA, Inc.$39
  • plus $144 from 6 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$123
GSK3$64
Lilly USA, LLC3$60
Novartis2$46
Abbott2$46
Genentech USA, Inc.2$39
Pfizer2$36
AbbVie(2 entities)2$28
AstraZeneca1$23
Amgen1$23
Dexcom, Inc.1$21
Merck1$12

How this compares

$521 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$61,896
Medicare patients
123
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$150,581
JardianceEmpagliflozin36$46,383
EliquisApixaban29$38,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$35,548
JanuviaSitagliptin Phosphate16$24,762
MounjaroTirzepatide13$22,751
Janumet XrSitagliptin Phos/Metformin Hcl13$13,277
Tresiba Flextouch U-200Insulin Degludec14$12,701
LinzessLinaclotide16$11,903
Rosuvastatin Calcium480$5,679
SynthroidLevothyroxine Sodium44$5,170
Atorvastatin Calcium472$4,227
Levothyroxine Sodium248$2,603
Metformin Hcl ErMetformin Hcl127$2,018
Omeprazole107$1,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$150,58174 claims
PfizerEliquis$36$38,19829 claims
MerckJanuvia, Janumet Xr$12$38,03829 claims
GSKTrelegy Ellipta$64$35,54825 claims
Lilly USA, LLCMounjaro$60$22,75113 claims
AbbVieLinzess, Synthroid$28$17,07360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →